GB201820320D0 - Bicyclic peptide ligands specific for FAPalpha - Google Patents

Bicyclic peptide ligands specific for FAPalpha

Info

Publication number
GB201820320D0
GB201820320D0 GBGB1820320.8A GB201820320A GB201820320D0 GB 201820320 D0 GB201820320 D0 GB 201820320D0 GB 201820320 A GB201820320 A GB 201820320A GB 201820320 D0 GB201820320 D0 GB 201820320D0
Authority
GB
United Kingdom
Prior art keywords
fapalpha
peptide ligands
ligands specific
bicyclic peptide
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1820320.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleRD Ltd
Original Assignee
BicycleRD Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleRD Ltd filed Critical BicycleRD Ltd
Priority to GBGB1820320.8A priority Critical patent/GB201820320D0/en
Publication of GB201820320D0 publication Critical patent/GB201820320D0/en
Priority to CN201980089032.4A priority patent/CN113507961A/zh
Priority to US17/309,628 priority patent/US20220008545A1/en
Priority to JP2021534207A priority patent/JP2022515721A/ja
Priority to PCT/GB2019/053535 priority patent/WO2020120979A1/en
Priority to EP19823955.0A priority patent/EP3894005A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB1820320.8A 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha Ceased GB201820320D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1820320.8A GB201820320D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha
CN201980089032.4A CN113507961A (zh) 2018-12-13 2019-12-13 FAPα特异性的双环肽配体
US17/309,628 US20220008545A1 (en) 2018-12-13 2019-12-13 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa
JP2021534207A JP2022515721A (ja) 2018-12-13 2019-12-13 FAPαに特異的な二環式ペプチドリガンド
PCT/GB2019/053535 WO2020120979A1 (en) 2018-12-13 2019-12-13 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPα
EP19823955.0A EP3894005A1 (en) 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for fap-alpha

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1820320.8A GB201820320D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha

Publications (1)

Publication Number Publication Date
GB201820320D0 true GB201820320D0 (en) 2019-01-30

Family

ID=65147028

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1820320.8A Ceased GB201820320D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha

Country Status (6)

Country Link
US (1) US20220008545A1 (cg-RX-API-DMAC7.html)
EP (1) EP3894005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022515721A (cg-RX-API-DMAC7.html)
CN (1) CN113507961A (cg-RX-API-DMAC7.html)
GB (1) GB201820320D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020120979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
EP4706663A3 (en) * 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
EP3615550A1 (en) * 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof

Also Published As

Publication number Publication date
EP3894005A1 (en) 2021-10-20
JP2022515721A (ja) 2022-02-22
US20220008545A1 (en) 2022-01-13
CN113507961A (zh) 2021-10-15
WO2020120979A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
IL290090A (en) A complex of heterotandem bicyclic peptides
IL283873B1 (en) Bicyclic peptide ligands specific for MT1-MMP
HUE073547T2 (hu) EPHA2-re specifikus, biciklusos peptidligandumok
GB201721265D0 (en) Bicyclic peptide ligands specific for EphA2
GB201820325D0 (en) Bicyclic peptide ligands specific for psma
GB201820295D0 (en) Bicyclic peptide ligands specific for MT1-MMP
GB201820316D0 (en) Bicyclic peptide ligands specific for IL-17
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
HK40050152A (en) Bicyclic peptide ligands specific for nectin-4
GB201820956D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201720934D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201820312D0 (en) Bicyclic peptide ligands specific for IL-6
GB201818603D0 (en) Bicyclic peptide ligands specific for epha2
GB201820314D0 (en) Bicyclic peptide ligands specific for KLK7
GB201820324D0 (en) Bicyclic peptide ligands specific for vegf
GB201712693D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201820318D0 (en) Bicyclic peptide ligands specific for cathepsin G
GB201820326D0 (en) Bicyclic peptide ligands specific for epha3
GB201820313D0 (en) Bicyclic peptide ligands specific for KLK5
GB201820321D0 (en) Bicyclic peptide ligands specific for MMP9
GB201820310D0 (en) Bicyclic peptide ligands specific for Hsp90

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)